ADB-B / ADB-BUTINACA

Buy ADB-B / ADB-BUTINACA Online

Buy laboratory-grade ADB-B / ADB-BUTINACA (99.9%+ purity) directly from ChemCentR.com – the premier supplier for forensic laboratories, toxicology reference collections, and advanced cannabinoid research worldwide.

ADB-BUTINACA (also known as ADB-BINACA or ADB-B) is an extremely potent third-generation indazole-based synthetic cannabinoid developed in 2019. Chemical name: N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-butyl-1H-indazole-3-carboxamide It is currently one of the most frequently detected new synthetic cannabinoids in seized “Spice” products globally (EMCDDA 2023–2025).

Full Technical Specifications of ADB-B / ADB-BUTINACA

• IUPAC name: N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-butyl-1H-indazole-3-carboxamide
• CAS Number: 2682867-77-3
• Molecular Formula: C₁₈H₂₆N₄O₂
• Molecular Weight: 330.43 g/mol
• Appearance: White to off-white crystalline powder
• Purity: ≥ 99.9% (HPLC, GC-MS, qNMR verified)
• Form: Free base
• Solubility: Soluble in DMSO, acetonitrile, methanol; low water solubility
• Storage: –20 °C in sealed, light-protected container
• Stability: > 36 months when properly stored

Why Forensic & Research Labs Choose ADB-B / ADB-BUTINACA from ChemCentR.com

• Full analytical package included (CoA + HPLC + GC-MS + ¹H-NMR + ¹³C-NMR)
• Primary reference material for LC-MS/MS and GC-MS screening libraries
• Essential for confirmation of ADB-B / ADB-BUTINACA metabolites (5-OH-ADB-B, ADB-B-4-en, etc.)
• Currently the #1 emerging synthetic cannabinoid in Europe, North America, and Asia (UNODC 2025 reports)

Documented Effects & Toxicity Profile (Harm-Reduction & Research Information Only)

ADB-B / ADB-BUTINACA is strictly a research chemical and NOT for human consumption. Real-world clinical and postmortem data from misuse (usually via vaping or smoking high-potency blends) show extreme danger:

Commonly Reported Effects from Misuse

• Rapid-onset, overwhelming sedation (“zombie-like” state)
• Intense cannabis-like high lasting 1–4 hours
• Heavy body load and motor impairment
• Dissociation and confusion

Known Severe Adverse Effects & Case Reports

• Profound bradycardia and hypotension (heart rate <40 bpm documented)
• Prolonged coma and respiratory depression requiring intubation
• Acute kidney injury (multiple confirmed cases)
• Hypothermia
• Seizures and status epilepticus
• Severe agitation alternating with catatonia
• Psychosis lasting days to weeks
• Rhabdomyolysis
• At least 70+ confirmed fatalities worldwide (2022–2025) directly linked to ADB-B / ADB-BUTINACA or its close analogs
• Extremely narrow safety margin – doses above 2–3 mg have caused life-threatening toxicity

Critical Warning: ADB-B / ADB-BUTINACA is considered 50–100× more potent than traditional synthetic cannabinoids like 5F-MDMB-PINACA. Even microgram-level mis-dosing has caused death.

Current Legal Status (November 2025)

• United Nations: Internationally controlled (Schedule II, March 2024)
• USA: Schedule I (DEA emergency scheduling 2023, permanent 2024)
• European Union: Controlled in all 27 member states
• United Kingdom: Class B
• China: Fully banned (class-wide indazole coverage)
• Australia, Canada, Japan, Russia – explicitly prohibited

ChemCentR.com supplies ADB-B / ADB-BUTINACA exclusively to licensed forensic laboratories, universities, and government agencies with valid permits.

Order ADB-B / ADB-BUTINACA Today – ChemCentR.com

Available in sealed 10 mg to 1 g reference quantities with complete analytical data package. Same-day dispatch | Discreet, tracked international shipping | Institutional invoice & crypto payment accepted.

For forensic, analytical, and scientific research only – strictly prohibited for human use.

Secure the highest-purity ADB-B / ADB-BUTINACA reference standard available worldwide — only from ChemCentR.com.